NCT06479447 Patient Outcome Reporting for Timely Assessments of Life With Post-Traumatic Stress Disorder
| NCT ID | NCT06479447 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | PTSD |
| Study Type | INTERVENTIONAL |
| Enrollment | 17,000 participants |
| Start Date | 2024-07-15 |
| Primary Completion | 2026-07-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 17,000 participants in total. It began in 2024-07-15 with a primary completion date of 2026-07-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to implement and evaluate a more timely approach to post-traumatic stress disorder (PTSD) diagnosis and management, entitled Patient Outcome Reporting for Timely Assessments of Life with Post-Traumatic Stress Disorder (PORTAL-PTSD) in a primary care setting with a high prevalence of trauma, specifically the South Side of Chicago, in partnership with Chicago Family Health Center (CFHC).
Eligibility Criteria
Patient Inclusion Criteria: * Age ≥18 years * Had an appointment at the study site in the last 24 months * Were not screened for PTSD in the last 12 months Exclusion Criteria: * N/A
Contact & Investigator
Neda Laiteerapong, MD, MS
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06479447 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06479447 currently recruiting?
Yes, NCT06479447 is actively recruiting participants. Contact the research team at akagarmanova@bsd.uchicago.edu for enrollment information.
Where is the NCT06479447 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States.
Who is sponsoring the NCT06479447 clinical trial?
NCT06479447 is sponsored by University of Chicago. The principal investigator is Neda Laiteerapong, MD, MS at University of Chicago. The trial plans to enroll 17,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.